Table 2 The levels of LDL-C at baseline and follow up in each arm of included trials
Authors | Trial name | Management in each arm | N | LDL-C level | |
|---|---|---|---|---|---|
At baseline | At follow-up | ||||
Tardif JC | A-PLUS | Avasimibe50 | 108 | 92.8 ± 1.7 | 100* |
Tardif JC | A-PLUS | Avasimibe250 | 98 | 93.4 ± 1.6 | 101.9* |
Tardif JC | A-PLUS | Avasimibe750 | 117 | 91.4 ± 1.6 | 101.4* |
Tardif JC | A-PLUS | Placebo | 109 | 89.6 ± 1.6 | 91.1* |
Okazaki S | ESTABLISH | Control | 24 | 123.9 ± 35.3 | 119.4 ± 24.6 |
Okazaki S | ESTABLISH | Atorvastatin | 24 | 124.6 ± 34.5 | 70.0 ± 25.0 |
Yokoyama M |  | Control | 30 | 131.5 ± 23# | 124.5 ± 24.1# |
Yokoyama M |  | Atorvastatin | 29 | 133 ± 13 | 87 ± 29 |
Nissen SE | REVERSAL | Atorvastatin | 253 | 150.2 ± 27.9 | 78.9 ± 30.2 |
Nissen SE | REVERSAL | Pravastatin | 249 | 150.2 ± 25.9 | 110.4 ± 25.8 |
Nissen SE | ACTIVATE | Pactimibe | 206 | 101.4 ± 27.7 | 91.3 |
Nissen SE | ACTIVATE | Placebo | 202 | 101.5 ± 31.1 | 86.4 |
Nissen SE | ILLUSTRATE | Atorvastatin | 446 | 84.3 ± 18.9 | 87.2 ± 22.6 |
Nissen SE | ILLUSTRATE | Atorva + torcetrapib | 464 | 83.1 ± 19.7 | 70.1 ± 25.4 |
Kawasaki M |  | Control | 17 | 152 ± 20 | 149 ± 24 |
Kawasaki M |  | Pravastatin | 18 | 149 ± 19 | 102 ± 13 |
Kawasaki M |  | Atorvastatin | 17 | 155 ± 22 | 95 ± 15 |
Hiro T | JAPAN-ACS | Pitavastatin | 125 | 130.9 ± 33.3 | 81.1 ± 23.4 |
Hiro T | JAPAN-ACS | Atorvastatin | 127 | 133.8 ± 31.4 | 84.1 ± 27.4 |
Nissen SE | ASTEROID | Rosuvastatin | 349 | 130.4 ± 34.3 | 60.8 ± 20.0 |
Takayama T | COSMOS | Rosuvastatin | 126 | 140.2 ± 31.5 | 82.9 ± 18.7 |
Lee CW | ARTMAP | Atorvastatin | 143 | 110 ± 31 | 56 ± 18 |
Lee CW | ARTMAP | Rosuvastatin | 128 | 109 ± 31 | 53 ± 18 |
Yamada T | REACH | Atorvastatin | 26 | 123 ± 17 | 83 ± 22 |
Yamada T | REACH | Control | 32 | 115 ± 14 | 115 ± 30 |
Nasu K |  | Fluvastatin | 40 | 144.9 ± 31.5 | 98.1 ± 12.7 |
Nasu K |  | Control | 39 | 122.3 ± 18.9 | 121.0 ± 21.2 |
Nicholls SJ | SATURN | Atorvastatin | 519 | 119.9 ± 28.9 | 70.2 ± 1.0 |
Nicholls SJ | SATURN | Rosuvastatin | 520 | 120.0 ± 27.3 | 62.6 ± 1.0 |
Hong MK |  | Simvastatin | 50 | 119 ± 30 | 78 ± 20 |
Hong MK |  | Rosuvastatin | 50 | 116 ± 28 | 64 ± 21 |
Tani S |  | Pravastatin | 52 | 130 ± 38 | 104 ± 20 |
Tani S |  | Control | 23 | 123 ± 28 | 120 ± 30 |
Rodés-C Bef | ERASE | Statins before ACS | 38 | 71 ± 23 | 77 ± 25 |
Rodés-C Aft | ERASE | Statins after ACS | 36 | 100 ± 30 | 63 ± 17 |
Jensen LO |  | Simvastatin | 40 | 158.7 ± 30.6 | 85.1 ± 22.1 |
Nissen SE | PERISCOPE | Statins + Gli | 181 | 94.4 ± 32.9 | 96.1 ± 30.4 |
Nissen SE | PERISCOPE | Statins + Pio | 179 | 93.5 ± 30.7 | 95.6 ± 28.9 |
Nissen SE | STRADIVARIUS | Statins + Rim | 335 | 91.9 ± 27.9 | 87.6 ± 30.5 |
Nissen SE | STRADIVARIUS | Statins + Con | 341 | 89.5 ± 32.2 | 86.3 ± 30.3 |